Great success for India! The ‘Made in India’ corona vaccine will arrive on August 15

Amid the growing number of corona infections, there is some comforting news. A few days ago, it was reported that the first vaccine against coronavirus in India was called COVAXIN. But everyone was also waiting for the launch of the vaccine. The wait is finally over, with the Made in India vaccine for corona patients coming in by August 15. Following the human trial of the vaccine, the vaccine can be launched in India by Bharat Biotech, ICMR till August 15. Permission has been granted for the first human trial on July 7.

Corona will end havoc Covid-19 vaccine may come within a year WHO chief

Corona vaccine has been developed in India by Bharat Biotech. It is said that the vaccine will be launched by Bharat Biotech and ICMR. What is special is that this vaccine is allowed for human testing. Bharat Biotech has been awarded by the Drug Controller General of India (DCGI). According to a letter issued by ICMR, registration for human trials will start from July 7. After that, if all the tests are successful, the vaccine is expected to be launched by August 15. First of all, it is being said that this vaccine of Bharat Biotech will be launched in the market during Corona.

Coronavirus vaccine


In particular, Hyderabad-based pharma company Bharat Biotech had recently claimed that phase-1 and phase-2 human tests of the vaccine had also received a green signal from DCGI. Testing will begin in the first week of July, the company said.

Coronavirus Vaccine Made by India

The COVAXIN vaccine has been developed by BBIL in association with ICMR’s National Institute of Virology (NIV). To make this vaccine, NIV isolated a strain of the coronavirus from the body of a patient who was infected with the corona but had no symptoms. The strain was then sent to BBIL. BBIL ​​developed a dormant vaccine from that strain. The vaccine has also been developed from the deadly virus at Bharat Biotech’s BSL-3 High Containment Facility in Hyderabad’s Genome Valley to prevent the drug from affecting patients. The inactive vaccine record so far is good in terms of safety.

Exit mobile version